Smith+Nephew Signs Distribution Agreement with SI-BONE

Smith+Nephew signed a distribution agreement with SI-BONE, focused on their iFuse TORQ portfolio. This collaboration expands the Smith+Nephew portfolio offerings for percutaneous pelvic fracture fixation procedures and bolsters their position in high-frequency, high-impact trauma procedures.

The iFuse TORQ portfolio includes iFuse TORQ TNT and iFuse TORQ implants, offering indications for pelvic fracture fixation and fusion of the sacroiliac (SI) joint. Specifically, iFuse TORQ TNT is designed to address the anatomical and bone density needs of the sacrum and ilium.

iFuse TORQ TNT represents the next generation of technology for pelvic fracture fixation and SI joint fusion, providing a unique market advantage:

• FDA Breakthrough Device Designation: Recognized for its potential to provide more effective treatment of pelvic fractures compared to traditional cannulated screws.
• NTAP: Eligible for a Medicare New Technology Add-on Payment, which may provide up to $4,136 in additional reimbursement per procedure for hospitals using iFuse TORQ TNT.

Smith+Nephew will also have access to the broader iFuse TORQ portfolio alongside SI-BONE’s current sales channel, expanding the ability to serve surgeons and patients in this high-need area.

“We’re incredibly excited to partner with SI-BONE,” said Scott Gunn, Vice President Trauma, Extremities and Shoulder. “This collaboration reflects a shared commitment to innovation, clinical excellence, and improving patient outcomes. By combining SI-BONE’s industry leadership with Smith+Nephew’s established commercial platform, we see a meaningful opportunity to expand access to differentiated solutions, deepen surgeon engagement, and drive sustainable growth.”

Source: Smith+Nephew